Liu, C., Hu, S., Xu, X., et al. (2022) Evaluation of Tumour Heterogeneity by (18)F-Fluoroestradiol PET as a Predictive Measure in Breast Cancer Patients Receiving Palbociclib Combined with Endocrine Treatment. Breast Cancer Research, 24, Article No. 57.
https://doi.org/10.1186/s13058-022-01555-7

has been cited by the following article:

• TITLE: 18F-FES PET/CT Research Progress in the Diagnosis and Treatment of Breast Cancer

  AUTHORS: Jiahang He, Hua Pang

  KEYWORDS: 18F-FES, 18F-FDG, PET/CT, Breast Cancer, ER

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.12 No.1, January 19, 2024

  ABSTRACT: Estrogen receptor(ER) is a vital biomarker in the development and development of breast cancer, and its status has great clinical value in clinical treatment strategy, endocrine therapy efficacy prediction, and breast cancer prognosis. By specifically combining 18F-FES with ER, 18F-FES PET/CT imaging uses standard uptake value(SUV) to semi-quantitatively reflect the distribution of ER and its biological activity in patients, and assesses the expression of ER in breast cancer patients about primary and metastases before or after treatment, to provide a basis for personalized treatment of breast cancer. In this review, we will review the imaging principles of a new ER detection method 18F-FES PET/CT, and the research progress in the clinical application of breast cancer, and compare its diagnostic and treatment value with non-specific tumor imaging 18F-FDG PET/CT in breast cancer.